Prognostic impact of education level of patients with advanced non-small cell lung cancer enrolled in clinical trials
Massimo Di Maïo(University of Siena), Cesare Gridelli(Azienda Ospedaliera S.Giuseppe Moscati), Vittorio Gebbia(Università degli Studi di Enna Kore), Pasqualina Giordano, Ciro Gallo(University of Campania "Luigi Vanvitelli"), Claudia Sandomenico, Paolo Maione(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Antônio Rossi(Università Campus Bio-Medico), Francesco Carrozza(Ospedale per gli Infermi), Alessandro Morabito(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Adolfo Favaretto(Istituto Oncologico Veneto), Bruno Daniele(Azienda Ospedaliera G.Rummo), Maria Carmela Piccirillo(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Sergio Robbiati, Gennaro Daniele(Università Cattolica del Sacro Cuore), Francovito Piantedosi(Ospedale Monaldi), Domenico Bilancia(Azienda Ospedaliera Ospedale San Carlo Borromeo), Raffaele Costanzo, Francesco Perrone(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Alfonso Illiano, Elena Piazza(Luigi Sacco Hospital), Santi Barbera, Anna Ceribelli(St. Eugenio Hospital), Gaetano Rocco(Memorial Sloan Kettering Cancer Center), S. Cigolari(Ospedali Riuniti San Giovanni di Dio e Ruggi d'Aragona), Simona Signoriello(University of Campania "Luigi Vanvitelli")
Cited by 22
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
|Journal of Clinical Oncology|2019|1.8k
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial
|The Lancet Oncology|2019|1.7k
Non-small-cell lung cancer
|Nature Reviews Disease Primers|2015|1.1k